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Aims Insulin causes sodium retention and hypoglycaemia and its use is associated with worse outcomes in heart failure
(HF) with reduced ejection fraction. We have investigated whether this is also the case in HF with preserved ejection
fraction (HFpEF).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Methods
and results
We examined the association between diabetes/diabetes treatments and the risk of the primary composite
of cardiovascular death or HF hospitalization, as well as other outcomes in adjusted analyses in CHARM-Preserved
(left ventricular ejection fraction ≥ 45%), I-Preserve and TOPCAT (Americas) pooled. Of 8466 patients, 2653 (31%)
had diabetes, including 979 (37%) receiving insulin. Patients receiving insulin were younger, had a higher body mass
index, prevalence of ischaemic aetiology, N-terminal pro-B-type natriuretic peptide and use of diuretics, worse
New York Heart Association class and signs and symptoms, and worse quality of life and renal function, compared
to patients with diabetes not on insulin. Among the 1398 patients with echocardiographic data, insulin use was
associated with higher left ventricular end-diastolic pressure and more diastolic dysfunction than in other participants.
The primary outcome occurred at a rate of 6.3 per 100 patient-years in patients without diabetes, and 10.2 and 17.1
per 100 patient-years in diabetes patients without and with insulin use, respectively [fully adjusted hazard ratio (aHR)
insulin-treated diabetes vs. other diabetes: 1.41, 95% confidence interval (CI) 1.23–1.63, P< 0.001]. The adjusted
HR is 1.67 (95% CI 1.20–2.32, p= 0.002) for sudden death (insulin-treated diabetes vs. other diabetes).
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Conclusions Insulin use is associated with poor outcomes in HFpEF. Although we cannot conclude a causal association, the safety
of insulin and alternative glucose-lowering treatments in HF needs to be evaluated in clinical trials.
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Introduction
Type 2 diabetes mellitus is common in patients with heart fail-
ure and preserved ejection fraction (HFpEF), with a reported
prevalence of around 30–40%.1 It has been suggested that
diabetes plays a key pathophysiological role in the develop-
ment of HFpEF, and is an independent predictor of adverse
outcomes in HFpEF.1–4 The importance of better understand-
ing the safety and possible benefits of anti-diabetes agents in
patients with established heart failure (HF) is underscored by
recent cardiovascular (CV) outcome trials in diabetes mellitus.
Thiazolidinediones and, possibly, certain dipeptidyl peptidase-4
inhibitors increase the risk of HF hospitalization,5,6 glucagon-like
peptide-1 receptor agonists have shown a neutral effect,7–10 and
more recently, three sodium–glucose co-transporter 2 (SGLT2)
inhibitors, empagliflozin, canagliflozin and dapagliflozin, have shown
a significant reduction in HF hospitalization.7–10
Insulin, a traditional second-line treatment for type 2 diabetes,
leads to sodium and water retention, weight gain and hypogly-
caemia, with resultant sympathetic nervous system activation.11,12
Theoretically, insulin may be detrimental to patients with concomi-
tant HF, but this has yet to be tested in a randomized clinical trial in
patients with established HF. In a post-hoc analysis of the Candesar-
tan in Heart failure: Assessment of Reduction in Mortality and mor-
bidity (CHARM) trial, insulin therapy was associated with higher
risks of mortality and HF hospitalization in patients with HF and
reduced ejection fraction (HFrEF) and similar findings have been
reported from other HFrEF clinical trials.13,14 Likewise, adverse
outcomes associated with insulin treatment were observed in HF
patients included in a large administrative registry from Italy.14
However, little is known about the characteristics of and clinical
outcomes in HFpEF patients with diabetes taking insulin.15 HFpEF
may be a more insulin-resistant state than HFrEF and it has been
suggested that insulin plays a role in the myocardial changes char-
acterizing the HFpEF phenotype.16 Therefore, we examined the
relationship between baseline insulin therapy and clinical outcomes
in patients enrolled in the three largest randomized trials in HFpEF.
Methods
Study population
For these analyses, we combined patients enrolled in the
CHARM-Preserved trial,17 the Irbesartan in Heart Failure with
Preserved Ejection Fraction (I-Preserve) trial18 and the Treatment
of Preserved Cardiac Function Heart Failure with an Aldosterone
Antagonist (TOPCAT) trial.19 The design and main results of these
trials have been published. Briefly, CHARM-Preserved compared
candesartan with placebo in 3023 HF patients in New York Heart
Association (NYHA) functional class II–IV with a left ventricular ejec-
tion fraction (LVEF) > 40%. Patients in NYHA class II were required
to have had a hospital admission for a cardiac reason within the past
6months.17 In I-Preserve, 4128 patients aged ≥ 60 years in NYHA
class II–IV with a LVEF ≥ 45% were randomized to receive irbesartan
or placebo. Patients in NYHA class II were eligible if they had a HF
hospitalization within the previous 6months.18 In TOPCAT, 3445
patients aged ≥ 50 years in NYHA class II–IV with a LVEF ≥ 45% were ..
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.. randomized to receive spironolactone or placebo; patients were eligi-
ble if they had been hospitalized for HF within the past 12months, or
had an elevated plasma natriuretic peptide level within 60 days before
randomization [i.e. B-type natriuretic peptide (BNP) ≥ 100 pg/mL or
N-terminal pro-BNP (NT-proBNP) ≥ 360 pg/mL].19
For the present analysis, patients with a LVEF < 45% in CHARM-
Preserved were excluded to ensure a consistent LVEF entry threshold
across trials. Patients from Russia or Georgia in TOPCAT were also
excluded because of substantially lower event rates in this region
of enrolment compared to those in the Americas and there was
uncertainty about whether they had HF.20 All trials were approved by
the ethics committee in each study centre and all patients gave written
informed consent.
Diabetes status and insulin use
at baseline
In each trial, investigators completed a case report form in which they
were asked to state whether patients had diabetes and, if so, how
it was treated (i.e. with insulin, oral therapy and diet control). The
specific type of diabetes (type 1 or type 2) was not recorded in any
of the trials. The age of onset of diabetes was recorded in two of the
three trials (i.e. CHARM-Preserved and TOPCAT); of these, 66 (4.4%)
patients were diagnosed under 20 years of age. We aimed to examine
the effect of insulin use in patients with type 2 diabetes and HFpEF,
and analyses excluding these 66 patients, presumably with type 1
diabetes, are presented in the online supplementary Table S1–S5 and
Figure S1). Type 1 diabetes is clearly different because there is complete
absence of pancreatic insulin production and exogenous insulin therapy
is mandatory from the outset, unlike in type 2 diabetes.
Outcomes
The primary outcome was a composite of CV death or HF hospi-
talization in CHARM-Preserved, all-cause death or protocol-specified
CV hospitalization in I-Preserve, and a composite of CV death, HF
hospitalization or aborted cardiac arrest in TOPCAT. For this anal-
ysis, we specified the following outcomes of interest: the composite
of CV death or first HF hospitalization and its individual components,
as well as all-cause death.We also examined the twomain modes of CV
death, i.e. sudden death and pump failure death. In each trial, potential
endpoints were adjudicated by an independent committee using simi-
lar pre-specified criteria (the same committee adjudicated the events
in two of the three trials, i.e. CHARM-Preserved and TOPCAT).
Statistical analyses
Baseline characteristics were summarized as means with standard
deviations for continuous variables and frequencies with percentages
for categorical variables. Differences in baseline characteristics accord-
ing to diabetes status and insulin use were examined using ANOVA
for continuous variables with Bonferroni correction for multiple com-
parisons and the 𝜒2 test for categorical variables. Duration of dia-
betes, the Minnesota Living with Heart Failure (MLWHF) score, Kansas
City Cardiomyopathy Questionnaire (KCCQ) clinical summary score
and NT-proBNP were not normally distributed and therefore were
summarized as medians with interquartile ranges and analysed using
the Kruskal–Wallis test with Dunn’s test and a Bonferroni correction
for multiple comparisons. Event rates for the outcomes of interest
were calculated per 100 patient-years of follow-up and illustrated using
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Kaplan–Meier curves; cumulative incidence curves are presented in
online supplementary Figure S1.
Cox proportional hazards regression analysis was used to calcu-
late the hazard ratio (HR) for each outcome with the comparisons
of insulin-treated diabetes vs. no diabetes and non-insulin-treated dia-
betes vs. no diabetes. The proportional hazards regression analyses
were also performed with adjustment for a number of confounding
variables, including age, sex, race, heart rate, diastolic blood pressure,
LVEF, NYHA class III/IV (vs. I/II), body mass index (BMI), HF hospi-
talization within the past 6months, history of myocardial infarction,
hypertension, or atrial fibrillation, estimated glomerular filtration rate
(eGFR), and log-transformed NT-proBNP with simple imputation of
eGFR and NT-proBNP using the missing indicator method; sensitivity
analyses including only patients with complete NT-proBNP data are
shown in online supplementary Tables S4 and S5). Within-trial cluster-
ing was taken into consideration with the use of shared frailty models.
The proportional-hazards assumption was examined with the use of
the Schoenfeld residuals.
As patients with diabetes treated with insulin tend to have a longer
standing diabetes than those not on insulin, we compared the risk of
each outcome in patients with diabetes on insulin with those not on
insulin further adjusting for the duration of diabetes in addition to the
confounders mentioned above.
For patients with available echocardiographic data (745 patients in
I-Preserve and 653 patients in TOPCAT, respectively), we compared
the measurements of left ventricular structure and left ventricular
systolic and diastolic properties according to diabetes status and insulin
use at baseline.
A two-sided P-value < 0.05 was considered significant. All analyses
were performed using Stata version 15 (Stata Corp., College Station,
TX, USA).
Results
Overall, 10 596 patients were enrolled in CHARM-Preserved,
I-Preserve and TOPCAT. Of these, 450 patients from
CHARM-Preserved had a LVEF < 45% and therefore were
excluded. A further 1678 patients enrolled from Russia/Georgia
in TOPCAT and two patients with missing information on diabetes
status were also excluded, leaving 8466 patients for analysis. A
total of 2653 (31%) patients had diabetes at baseline, of which
979 (37%) patients were treated with insulin. Patients treated
with insulin, on average, had a much longer history of diabetes
(16 years) than those not on insulin (7 years) (Table 1).
Baseline characteristics
Table 1 shows the patient characteristics according to diabetes sta-
tus and insulin use at baseline. Patients with diabetes who received
insulin were younger (68 years) and less often of white race
(83%), compared to patients with diabetes not on insulin (70 years
and 85%, respectively) or patients without diabetes (71 years and
92%, respectively). The average BMI was highest in insulin-treated
patients with diabetes (34 kg/m2), intermediate in non-insulin-
treated patients with diabetes (32 kg/m2), and lowest in those with-
out diabetes (29 kg/m2). The opposite was true for the average
diastolic blood pressure, despite a similar systolic blood pressure
across groups (Table 1). ..
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.. Patients with diabetes receiving insulin more often had an
ischaemic aetiology (45%) than either those with diabetes not on
insulin (37%) or those without diabetes (35%). They were more
likely to have undergone coronary revascularization than the latter
two groups (39% vs. 27% and 19%, respectively). There was a
similar difference in the prevalence of dyslipidaemia (75%, 62%,
and 45% of each group, respectively) and the history of prior HF
hospitalization (49%, 43%, and 40% of each group, respectively).
Patients with diabetes, regardless of insulin use, had a higher
prevalence of myocardial infarction, hypertension and stroke than
patients without diabetes.
The use of loop diuretics was much more frequent in
insulin-treated patients (80%) than in those with diabetes not
on insulin (66%) and especially compared to those without
diabetes (56%), as was the use of lipid lowering agents (65%,
50%, and 35% of each group, respectively). There was also a
significant difference in the use of mineralocorticoid receptor
antagonists (30%, 23%, and 20% of each group, respectively) and of
angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers (76%, 71%, and 61%, respectively).
Although the mean LVEF differed little according to diabetes
status or the use of insulin, patients treated with insulin had worse
NYHA functional status, more HF-related signs and symptoms, and
worse health-related quality of life, as indicated by a substantially
higher MLWHF score and lower KCCQ clinical summary score
compared to patients with diabetes not on insulin and, in particular,
those without diabetes. For example, the proportion of patients
with oedema was much higher in patients with insulin-treated
diabetes than in the other two groups (64%, 54%, and 48%,
respectively).
The median plasma NT-proBNP concentration was highest
in insulin-treated individuals (581 pg/mL) and lowest in those
without diabetes (364 pg/mL), with an intermediate level in
patients with diabetes not treated with insulin (430 pg/mL). There
was a similar pattern in the proportion of patients with an
eGFR < 60mL/min/1.73m2 (53%, 32%, and 37% of each group,
respectively).
Echocardiographic measurements
Of the 1398 patients with echocardiographic data available, 495
(35%) had diabetes at baseline. There were 206 (42%) diabetes
patients on insulin treatment. The patients in this subset (and
the differences among them in relation to diabetes status) were
similar to those in the overall study cohort (online supplementary
Table S6).
Wall thickness, left ventricular mass and the proportion of
participants with left ventricular hypertrophy was higher among
those with diabetes not taking insulin than in those without
diabetes and highest in those with diabetes treated with insulin
(Table 2). Although there was no difference in LVEF, fractional
shortening and mitral lateral annular tissue velocity during systole
(S′ lateral) were lower in diabetic patients on insulin than the other
two groups. The higher early diastolic mitral inflow velocity (E)
and E/E’ ratio in diabetes patients treated with insulin, compared
to the other patient groups, suggested insulin-treated patients had
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Patient characteristics according to baseline diabetes mellitus status and insulin use in the combined data
sets of CHARM-Preserved (left ventricular ejection fraction ≥ 45%), I-Preserve and TOPCAT (Americas)
No DM
(n = 5813)
DM not on
insulin
(n = 1674)
DM on
insulin
(n = 979)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Overall DM not on
insulin
vs. no DM
DM on
insulin
vs. no DM
DM on
insulin
vs. not
on insulin
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 70.6± 9.4 69.9± 8.7 67.8± 8.4 <0.0001 0.017 <0.001 <0.001
Age at diabetes onset, years – 57.8±14.9 48.2±14.8 <0.0001
Duration of diabetes, years – 7 [3–13] 16 [10–24] <0.0001
Male sex 2724 (46.9) 837 (50.0) 447 (45.7) 0.0408 0.023 0.486 0.031
Race <0.0001 <0.001 <0.001 <0.001
White 5357 (92.2) 1429 (85.4) 808 (82.5)
Black 248 (4.3) 126 (7.5) 118 (12.1)
Asian 62 (1.1) 36 (2.2) 20 (2.0)
Other 146 (2.5) 83 (5.0) 33 (3.4)
Body mass index, kg/m2 29.4± 5.8 31.9± 6.7 34.0± 7.6 <0.0001 <0.001 <0.001 <0.001
Blood pressure, mmHg
Systolic 134.6±16.7 135.0±16.6 134.0±17.4 0.313 0.974 0.99 0.394
Diastolic 77.7±10.3 76.4±10.6 72.9±11.1 <0.0001 <0.001 <0.001 <0.001
Heart rate, b.p.m. 70.5±11.4 71.6±11.0 72.0±11.7 <0.0001 0.001 0.001 0.99
NYHA class III–IV 3262 (56.1) 998 (59.6) 600 (61.3) 0.0013 0.011 0.003 0.397
LVEF, % 58.2± 8.9 58.1± 8.8 58.1± 8.9 0.916 0.99 0.99 0.99
Aetiology, n (%) <0.0001 0.081 <0.001 <0.001
Ischaemic 1688 (34.9) 467 (36.9) 268 (44.7)
Hypertensive 2393 (49.5) 631 (49.9) 231 (38.5)
Other 755 (15.6) 167 (13.2) 101 (16.8)
HF duration 0.0017 0.001 0.109 0.374
≤ 1 year 2280 (47.2) 557 (44.1) 285 (47.5)
> 1 and ≤ 5 years 1800 (37.3) 454 (35.9) 204 (34.0)
> 5 years 752 (15.6) 253 (20.0) 111 (18.5)
Medical history
Current smoking 321 (11.4) 79 (9.0) 47 (7.3) 0.0036 0.047 0.003 0.249
HF hospitalization within the past 6months 2309 (39.7) 723 (43.2) 476 (48.6) <0.0001 0.011 <0.001 0.007
Myocardial infarction 1550 (26.7) 529 (31.6) 305 (31.2) <0.0001 <0.001 0.004 0.811
Angina 2565 (44.1) 765 (45.7) 454 (46.4) 0.278 0.254 0.19 0.736
CABG or PCI 1118 (19.2) 449 (26.8) 377 (38.5) <0.0001 <0.001 <0.001 <0.001
Hypertension 4566 (78.5) 1492 (89.1) 872 (89.1) <0.0001 <0.001 <0.001 0.964
Atrial fibrillation 1914 (32.9) 528 (31.5) 279 (28.5) 0.019 0.287 0.006 0.1
Stroke 481 (8.3) 184 (11.0) 114 (11.6) <0.0001 0.001 0.001 0.607
Dyslipidaemia 1773 (44.6) 748 (62.1) 539 (75.1) <0.0001 <0.001 <0.001 <0.001
Medications
Diuretics 4609 (79.4) 1433 (85.7) 873 (89.3) <0.0001 <0.001 <0.001 0.008
Loop 3243 (55.8) 1102 (65.9) 779 (79.7) <0.0001 <0.001 <0.001 <0.001
Thiazide 1708 (29.4) 434 (25.9) 217 (22.2) <0.0001 0.006 <0.001 0.03
Calcium channel blocker 2080 (35.8) 668 (39.9) 408 (41.7) <0.0001 0.002 <0.001 0.365
ACEI or ARB 3555 (61.2) 1187 (70.9) 743 (75.9) <0.0001 <0.001 <0.001 0.005
MRA 1151 (19.8) 382 (22.8) 289 (29.5) <0.0001 0.007 <0.001 <0.001
Beta-blocker 3524 (60.7) 1036 (61.9) 671 (68.6) <0.0001 0.36 <0.001 0.001
Digoxin 995 (17.1) 302 (18.1) 155 (15.8) 0.347 0.383 0.321 0.147
Antiarrhythmic agent 574 (9.9) 132 (7.9) 56 (5.7) <0.0001 0.014 <0.001 0.036
Antiplatelet 3346 (57.6) 1060 (63.4) 652 (66.7) <0.0001 <0.001 <0.001 0.086
Oral anticoagulant 1440 (24.8) 391 (23.4) 224 (22.9) 0.272 0.232 0.203 0.783
Lipid-lowering agent 2062 (35.5) 833 (49.8) 634 (64.8) <0.0001 <0.001 <0.001 <0.001
ECG findings
Atrial fibrillation/flutter 1113 (19.2) 309 (18.5) 146 (15.0) 0.0079 0.495 0.002 0.023
QRS duration, milliseconds 90 [80–108] 94 [80–110] 94 [82–112] 0.0006 0.0357 0.0007 0.2218
Bundle branch block 857 (14.8) 276 (16.5) 167 (17.2) 0.063 0.087 0.055 0.65
Left bundle branch block 247 (8.2) 59 (7.4) 30 (8.8) 0.662 0.446 0.705 0.413
Right bundle branch block 185 (6.2) 70 (8.8) 28 (8.3) 0.019 0.009 0.138 0.765
Left ventricular hypertrophy 1311 (22.6) 344 (20.6) 148 (15.2) <0.0001 0.073 <0.001 0.001
Symptoms and signs
Dyspnoea on exertion 2754 (97.7) 857 (97.5) 622 (97.2) 0.741 0.736 0.45 0.71
Orthopnoea 572 (20.4) 244 (27.9) 245 (38.5) <0.0001 <0.001 <0.001 <0.001
Paroxysmal nocturnal dyspnoea 320 (11.4) 124 (14.3) 117 (18.5) <0.0001 0.023 <0.001 0.028
Dyspnoea at rest 142 (7.7) 58 (12.3) 44 (16.9) <0.0001 0.001 <0.001 0.091
Jugular venous distention 533 (9.3) 181 (11.0) 123 (12.9) 0.0009 0.037 <0.001 0.146
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
978 L. Shen et al.
Table 1 Continued
No DM
(n = 5813)
DM not on
insulin
(n = 1674)
DM on
insulin
(n = 979)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Overall DM not on
insulin
vs. no DM
DM on
insulin
vs. no DM
DM on
insulin
vs. not
on insulin
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Oedema 2759 (47.5) 905 (54.1) 626 (63.9) <0.0001 <0.001 <0.001 <0.001
Rales 1258 (21.7) 370 (22.2) 235 (24.2) 0.214 0.646 0.08 0.241
Third heart sound 299 (6.2) 99 (7.8) 53 (8.8) 0.012 0.036 0.013 0.458
Hepatomegaly 647 (13.4) 207 (16.4) 63 (10.6) 0.002 0.006 0.054 0.001
Health-related quality of life
Minnesota Living With Heart Failure score 40 [26–56] 45 [27–62] 51 [33–70] <0.0001 0.0001 <0.0001 0.0004
KCCQ clinical summary score 65 [46–80] 58 [42–76] 52 [33–68] <0.0001 0.0006 <0.0001 0.0002
Laboratory measurements
eGFR, mL/min/1.73m2 71.5± 22.2 71.4± 24.8 62.7± 23.9 <0.0001 0.99 <0.001 <0.001
eGFR < 60mL/min/1.73m2 1451 (32.4) 518 (37.0) 457 (53.3) <0.0001 0.002 <0.001 <0.001
Haemoglobin, g/dL 13.9±1.6 13.5±1.7 12.9±1.7 <0.0001 <0.001 <0.001 <0.001
NT-proBNP, pg/mL 364 [139–1017] 430 [167–1041] 581 [207–1336] <0.0001 0.174 <0.0001 0.0024
Values are given as mean± standard deviation, n (%), or median [interquartile range].
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; DM, diabetes mellitus; ECG, electrocardiogram; eGFR, estimated glomerular
filtration rate; HF, heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type
natriuretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.
Age at diabetes onset and duration of diabetes were available in 716 (98%) patients from CHARM-Preserved and 779 (99%) from TOPCAT; NT-proBNP was available in 3838 (45%) patients; eGFR was
available in 6735 (80%) patients; haemoglobin was available in 5735 (68%) patients. Current smoking, dyspnoea on exertion, orthopnoea, paroxysmal nocturnal dyspnoea and dyspnoea at rest were not
recorded in I-Preserve. Dyslipidaemia was not recorded in CHARM-Preserved. Third heart sound and hepatomegaly were not recorded in TOPCAT. Left bundle branch block and right bundle branch
block were only available in I-Preserve.
Minnesota Living With Heart Failure score was available in 783 (30%) patients from CHARM-Preserved and 3148 (76%) patients from I-Preserve, and possible scores range from 0 to 105, with lower
scores indicating a better quality of life.
KCCQ clinical summary score was available in 1726 (98%) patients from TOPCAT, and possible scores range from 0 to 100, with higher scores indicating better health-related quality of life.
higher left ventricular end-diastolic pressure and more diastolic
dysfunction than the other participants. However, left atrial size
was lowest in diabetes patients treated with insulin compared to
the other two groups.
Clinical outcomes
Incidence rates and HRs for the risk of each outcome of inter-
est, according to diabetes status and insulin use at baseline, are
presented in Table 3 and Figure 1.
Composite outcomes and mortality
In unadjusted analyses, there was a stepwise increase in the rates
of each of the primary composite outcome, HF hospitalization,
CV death, and all-cause death across the no diabetes (reference
group), non-insulin-treated diabetes, and insulin-treated diabetes
groups. The rate of the primary composite outcome was 6.3 per
100 patient-years in patients without diabetes, and 10.2 and 17.1
per 100 patient-years in diabetes patients without and with insulin
use, respectively. A similar magnitude of difference was seen in the
rate of HF hospitalization (4.2, 7.1 and 13.3 per 100 patient-years
in each group, respectively). The elevated risks of these outcomes
persisted after adjustment for the prognostic variables including
NT-proBNP. Compared to individuals without diabetes, there was
a doubling in risk of the primary composite outcome in patients
on insulin [fully adjusted HR 2.19; 95% confidence interval (CI)
1.94–2.48; P< 0.001], whereas patients with diabetes not treated
with insulin had a 50% higher risk (HR 1.49; 95% CI 1.34–1.66;
P< 0.001). The same was also true for the risk of HF hospitalization ..
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.. (fully adjusted HR 2.25; 95% CI 1.95–2.60; P< 0.001, and 1.50; 95%
CI 1.32–1.71; P< 0.001, respectively) and, to a lesser extent, for
CV death (HR 1.95; 95% CI 1.63–2.33; P< 0.001, and 1.43; 95%
CI 1.23–1.65; P< 0.001, respectively) and for all-cause death (HR
1.87; 95% CI 1.61–2.16; P< 0.001, and 1.41; 95% CI 1.25–1.60;
P< 0.001, respectively).
Sudden death and pump failure death
In addition, we investigated the two main modes of CV death
(Table 3). Compared with patients without diabetes, patients on
insulin had a substantially higher risk of sudden death (fully adjusted
HR 2.55; 95% CI 1.93–3.37; P< 0.001) as well as pump failure
death (fully adjusted HR 2.14; 95% CI 1.47–3.11; P< 0.001). The
elevated risks were attenuated, but remained significantly higher, in
the other patients with diabetes not receiving insulin, with a fully
adjusted HR of 1.46 (95% CI 1.14–1.86; P = 0.003) for sudden
death and 1.83 (95% CI 1.36–2.46; P< 0.001) for pump failure
death, respectively.
We also examined the outcomes of interest among patients
with diabetes only (i.e. excluding those without diabetes in these
comparisons) (Table 4). Overall, compared to those not receiving
insulin, patients treated with insulin had significantly greater risks
for the primary composite, its individual components, all-cause
death, and, particularly, sudden death. However, insulin use was
not significantly associated with a higher risk of pump failure death.
These associations were largely unchanged with adjustment for
other prognostic variables including NT-proBNP and the duration
of diabetes.
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Table 2 Echocardiographic data according to baseline diabetes mellitus status and insulin use
Patients with data,
n (%)
No DM
(n = 903)
DM not on
insulin (n = 289)
DM on insulin
(n = 206)
P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age, years 72.1± 8.3 71.4± 8.4 68.8± 8.6 <0.0001
Male sex 370 (41.0) 156 (54.0) 98 (47.6) 0.0004
LV structure
End-diastolic dimension, cm 1291 (92) 4.8± 0.6 4.9± 0.6 4.8± 0.6 0.0139
End-diastolic volume, mL 1176 (84) 92.3± 35.5 98.0± 34.6 101.1± 32.8 0.0032
End-systolic dimension, cm 1267 (91) 3.2± 0.6 3.4± 0.5 3.4± 0.5 0.0003
End-systolic volume, mL 1176 (84) 35.8±19.0 38.5±18.4 39.4±16.4 0.0183
Septum wall thickness, cm 1331 (95) 1.06± 0.21 1.12± 0.22 1.21± 0.24 <0.0001
Posterior wall thickness, cm 1330 (95) 1.01± 0.20 1.07± 0.20 1.16± 0.22 <0.0001
Relative wall thickness 1283 (92) 0.44± 0.10 0.45± 0.11 0.49± 0.11 <0.0001
LV mass, g 1283 (92) 182.7± 65.4 204.8± 62.8 223.7± 72.1 <0.0001
LV mass index, g/m2 1278 (91) 95.7± 30.2 103.4± 28.2 106.4± 28.5 <0.0001
LV hypertrophya 1278 (91) 268 (32.9) 107 (40.5) 98 (49.2) <0.0001
LV systolic properties
Fractional shortening, % 1258 (90) 32.6± 8.4 31.0± 7.1 30.8± 5.7 0.0013
Stroke volume, mL 1176 (84) 56.6± 21.3 59.4± 21.2 61.7±19.8 0.0069
Ejection fraction, % 1234 (88) 61.9± 9.1 61.1± 8.8 60.9± 7.3 0.1929
S′ lateral, cm/s 889 (64) 7.8± 2.4 7.5± 2.4 7.2± 2.3 0.0222
LV diastolic properties
E, cm/s 1289 (92) 80.1± 28.4 88.6± 29.9 99.8± 28.7 <0.0001
A, cm/s 1063 (76) 78.8± 26.5 79.0± 27.1 79.6± 27.2 0.9434
E/A 1057 (76) 1.6± 8.0 1.6± 4.7 1.8± 4.8 0.9686
E’ lateral, cm/s 894 (64) 9.0± 3.6 8.7± 3.2 8.4± 3.1 0.1483
E’ septal, cm/s 888 (64) 7.0± 3.0 6.6± 2.4 6.3± 2.2 0.0124
E/E’ lateral 882 (63) 10.1± 4.7 11.4± 5.9 13.8± 6.0 <0.0001
E/E’ septal 874 (63) 13.0± 5.9 15.4± 7.3 17.9± 7.4 <0.0001
E deceleration time, ms 1283 (92) 210.0± 74.0 210.4± 67.8 200.3± 53.6 0.2241
Isovolumic relaxation time, ms 636 (45) 96.5± 22.5 94.6±19.9 87.5± 22.6 0.0295
Left atrial area, cm2 1267 (91) 21.8± 6.3 22.3± 6.0 20.6± 5.2 0.0144
Left atrial volume, mL 1091 (78) 74.2± 33.8 74.5± 33.7 63.7± 26.3 0.0006
Left atrial volume index, mL/m2 1084 (78) 39.5±17.8 37.9±17.6 31.2±14.2 <0.0001
Values are given as n (%), or mean± standard deviation.
A, peak late diastolic filling velocity during atrial contraction; DM, diabetes mellitus; E, peak early diastolic filling velocity; E’, mitral lateral and septal annular tissue velocity
during early filling; LV, left ventricular; S′ lateral, mitral lateral annular tissue velocity during systole.
aDefined as LV mass indexed to body surface area ≥115 g/m2 for men and ≥ 95 g/m2 for women.
We conducted a number of sensitivity analyses, including exclu-
sion of patients with age < 20 years at diabetes onset and
examination of only the subset of patients with echocardiographic
measures (online supplementary Tables S2–S5 and S7). None of
these additional analyses resulted in any major change to the over-
all findings.
Discussion
Previously we showed that, among patients with concurrent HFrEF
and diabetes, those treated with insulin have worse symptoms,
more signs of congestion and greater risks of death and HF
hospitalization compared with those not on insulin.14 We believe
our present report is the first to extend these observations to
patients with HFpEF, and we have also identified additional, novel
findings in this HF phenotype. ..
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. We found that HFpEF patients with diabetes, treated with insulin,
had a higher median NT-proBNP and evidence of more congestion
than those not treated with insulin, despite their younger age and
similar average LVEF and duration of HF. In keeping with prior
studies, we found that patients with diabetes had more echocar-
diographic left ventricular hypertrophy than those without and this
was especially true for patients treated with insulin. In keeping with
this, elevated early diastolic mitral inflow velocity (E) and E/E’ ratio
suggested greater diastolic dysfunction and increased left ventricu-
lar end-diastolic pressure in patients treated with insulin. Although
these individuals also had higher NT-proBNP levels (as described
above), consistent with this hypothesis, they had smaller left atrial
size. This apparent paradox may be explained by the lower preva-
lence of atrial fibrillation in patients treated with insulin, which
itself is an interesting finding that has been highlighted recently.21
Tan and colleagues suggested that differences in cardiac remod-
elling might explain the relative ‘protection’ HFpEF patients with
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Clinical outcomes according to baseline diabetes mellitus status and insulin use in the combined data sets of
CHARM-Preserved (left ventricular ejection fraction ≥ 45%), I-Preserve and TOPCAT (Americas)
Patients, n Event, n (%) Annual rate
per 100
person-years
(95% CI)
Unadjusted
HRa (95% CI)
Adjusted 1
HRa (95% CI)
Adjusted 2
HRa (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CV death or HF hospitalization
No DM 5813 1227 (21.1) 6.3 (6.0–6.7) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM not on insulin 1674 513 (30.7) 10.2 (9.4–11.2) 1.58 (1.42–1.75), P< 0.001 1.53 (1.37–1.70), P< 0.001 1.49 (1.34–1.66), P< 0.001
DM on insulin 979 416 (42.5) 17.1 (15.5–18.8) 2.46 (2.20–2.76), P< 0.001 2.37 (2.10–2.67), P< 0.001 2.19 (1.94–2.48), P< 0.001
HF hospitalization
No DM 5813 811 (14.0) 4.2 (3.9–4.5) 1.00 (Reference)
DM not on insulin 1674 354 (21.2) 7.1 (6.4–7.8) 1.62 (1.43–1.83), P< 0.001 1.54 (1.36–1.76), P< 0.001 1.50 (1.32–1.71), P< 0.001
DM on insulin 979 325 (33.2) 13.3 (12.0–14.9) 2.77 (2.43–3.16), P< 0.001 2.49 (2.16–2.87), P< 0.001 2.25 (1.95–2.60), P< 0.001
CV death
No DM 5813 678 (11.7) 3.2 (3.0–3.5) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM not on insulin 1674 259 (15.5) 4.6 (4.1–5.2) 1.42 (1.23–1.64), P< 0.001 1.45 (1.25–1.68), P< 0.001 1.43 (1.23–1.65), P< 0.001
DM on insulin 979 179 (18.3) 5.9 (5.1–6.8) 1.83 (1.55–2.17), P< 0.001 2.09 (1.75–2.50), P< 0.001 1.95 (1.63–2.33), P< 0.001
All-cause death
No DM 5813 1024 (17.6) 4.9 (4.6–5.2) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM not on insulin 1674 387 (23.1) 6.8 (6.2–7.6) 1.39 (1.23–1.56), P< 0.001 1.44 (1.27–1.62), P< 0.001 1.41 (1.25–1.60), P< 0.001
DM on insulin 979 267 (27.3) 8.8 (7.8–9.9) 1.74 (1.52–2.00), P< 0.001 2.02 (1.75–2.34), P< 0.001 1.87 (1.61–2.16), P< 0.001
Sudden death
No DM 5813 235 (4.0) 1.1 (1.0–1.3) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM not on insulin 1674 93 (5.6) 1.6 (1.3–2.0) 1.49 (1.17–1.90), P = 0.001 1.46 (1.14–1.87), P = 0.003 1.46 (1.14–1.86), P = 0.003
DM on insulin 979 76 (7.8) 2.5 (2.0–3.1) 2.38 (1.83–3.10), P< 0.001 2.68 (2.03–3.54), P< 0.001 2.55 (1.93–3.37), P< 0.001
Pump failure death
No DM 5813 158 (2.7) 0.8 (0.6–0.9) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM not on insulin 1674 69 (4.1) 1.2 (1.0–1.5) 1.61 (1.21–2.13), P = 0.001 1.90 (1.42–2.55), P< 0.001 1.83 (1.36–2.46), P< 0.001
DM on insulin 979 41 (4.2) 1.4 (1.0–1.8) 1.72 (1.21–2.44), P = 0.002 2.38 (1.64–3.44), P< 0.001 2.14 (1.47–3.11), P< 0.001
BMI, body mass index; CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; LVEF, left ventricular ejection
fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
Adjustment Model 1: age, sex, heart rate, diastolic blood pressure, LVEF, NYHA class III/IV, BMI, HF hospitalization within the past 6months, history of myocardial infarction, hypertension, and atrial
fibrillation.
Adjustment Model 2: age, sex, race, heart rate, diastolic blood pressure, LVEF, NYHA class III/IV, BMI, HF hospitalization within the past 6months, history of myocardial infarction, hypertension, and atrial
fibrillation, eGFR, and log NT-proBNP with simple imputation of eGFR and NT-proBNP.
aHRs for combined data were adjusted for within-trial clustering.
diabetes have against atrial fibrillation, although our data suggest
that this difference is confined to patients treated with insulin.
We also found that HFpEF patients with insulin-treated diabetes
had worse health-related quality of life and were twice as likely to
experience CV death or HF hospitalization, even after extensive
adjustment for other prognostic variables including NT-proBNP
and eGFR. These patients were at greater risk than not only
individuals without diabetes but also those with diabetes treated
with other glucose-lowering agents.
The importance of measuring patient-reported outcomes in HF
is now widely recognized and in the trials included in our analyses
the two most commonly used instruments, i.e. the MLWHF score
and the KCCQ, were employed.22,23 We found that patients with
diabetes on insulin had a substantially worse quality of life, with
the average value of the MLWHF score 6 and 11 (out of 105)
points higher (worse) compared to patients with diabetes not
on insulin and those without diabetes, respectively. Likewise, a
similar magnitude of incremental worsening of quality of life was
observed across groups when examined using the KCCQ clinical
summary score (6 and 13 points out of 100 worse, respectively).
As well as evidence of greater congestion, the worse health-related
quality of life may reflect higher BMI, more coronary heart disease
and greater renal impairment.24,25 It is particularly notable that,
whereas patient-reported outcomes were markedly different ..
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. among the groups examined, NYHA class (a physician-reported
outcome) was not. This suggests that physicians may not fully
appreciate the impact of diabetes on health-related quality of
life in patients with HFpEF and reinforces the value of using
patient-reported outcomes.
In addition to worse patient-reported outcomes, individuals with
diabetes, especially those treated with insulin, had worse clinical
outcomes compared to patients without diabetes. Although a few
studies have examined outcomes in HFpEF patients according to
diabetes status, individually they have been too small to compare
insulin-treated patients to those not receiving insulin, could not
adjust for all other important prognostic markers (particularly
natriuretic peptides), or had both limitations.26 We found that,
even after adjustment for NT-proBNP and other key prognostic
variables, use of insulin to treat diabetes was associated with
around a doubling in risks for the composite of HF hospitalization
or CV death, its individual components, and all-cause mortality, and
a 50% higher risk of these outcomes when other glucose-lowering
therapies were employed.
Another strength of our study was that it was large enough
to examine individual modes of death and these were adjudi-
cated. Notably, we found that the greater risk of CV death
was due to a higher rate of sudden death rather than pump
failure death in insulin-treated compared to non-insulin-treated
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Kaplan–Meier curves for clinical outcomes according to baseline diabetes mellitus (DM) status and insulin use in the combined
data sets of CHARM-Preserved (left ventricular ejection fraction ≥ 45%), I-Preserve and TOPCAT (Americas). Kaplan–Meier estimates of the
probability of cardiovascular (CV) death or first hospitalization for heart failure (HF) (A), CV death (B), first hospitalization for HF (C), all-cause
death (D), sudden death (E) and pump failure death (F).
patients with diabetes. This was an unexpected finding. A higher
risk for pump failure rather than sudden death might have been
predicted by the greater severity of symptoms and signs of con-
gestion in insulin-treated patients. It is possible, however, to pos-
tulate mechanisms leading to a greater risk of sudden death. ..
..
..
..
..
..
..
. The first relates to diabetes per se and, particularly, the devel-
opment of autonomic neuropathy, which can cause cardiac elec-
trical instability. The second relates to co-morbidity, especially
coronary artery disease which may predispose to ventricular
arrhythmias. Thirdly, insulin treatment and the associated risk
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 4 Clinical outcomes according to baseline insulin use in diabetic patients in the combined data sets of
CHARM-Preserved (left ventricular ejection fraction ≥ 45%), I-Preserve and TOPCAT (Americas)
Unadjusted HRa (95% CI) Adjusted 1 HRa (95% CI) Adjusted 2 HRa (95% CI) Adjusted 3 HRa (95% CI)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
CV death or HF hospitalization
DM not on insulin 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM on insulin 1.57 (1.38–1.79), P< 0.001 1.51 (1.32–1.73), P< 0.001 1.43 (1.25–1.64), P< 0.001 1.41 (1.23–1.63), P< 0.001
HF hospitalization
DM not on insulin 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM on insulin 1.72 (1.47–2.00), P< 0.001 1.58 (1.35–1.85), P< 0.001 1.46 (1.24–1.72), P< 0.001 1.45 (1.22–1.71), P< 0.001
CV death
DM not on insulin 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM on insulin 1.32 (1.09–1.60), P = 0.005 1.42 (1.17–1.74), P = 0.001 1.35 (1.11–1.66), P = 0.003 1.32 (1.07–1.63), P = 0.009
All-cause death
DM not on insulin 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM on insulin 1.29 (1.10–1.51), P = 0.002 1.38 (1.18–1.63), P< 0.001 1.30 (1.11–1.54), P = 0.002 1.27 (1.07–1.50), P = 0.007
Sudden death
DM not on insulin 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM on insulin 1.59 (1.17–2.16), P = 0.003 1.81 (1.32–2.49), P< 0.001 1.76 (1.28–2.42), P = 0.001 1.67 (1.20–2.32), P = 0.002
Pump failure death
DM not on insulin 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 1.00 (Reference)
DM on insulin 1.13 (0.76–1.67), P = 0.537 1.30 (0.86–1.94), P = 0.209 1.18 (0.78–1.78), P = 0.429 1.20 (0.78–1.83), P = 0.411
BMI, body mass index; CI, confidence interval; CV, cardiovascular; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HF, heart failure; HR, hazard ratio; LVEF,
left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.
Adjustment Model 1: age, sex, heart rate, diastolic blood pressure, LVEF, NYHA class III/IV, BMI, HF hospitalization within the past 6months, history of myocardial infarction,
hypertension, and atrial fibrillation.
Adjustment Model 2: age, sex, heart rate, diastolic blood pressure, LVEF, NYHA class III/IV, BMI, HF hospitalization within the past 6months, history of myocardial infarction,
hypertension, and atrial fibrillation, eGFR, and log NT-proBNP with simple imputation of eGFR and NT-proBNP.
Adjustment Model 3: age, sex, race, heart rate, diastolic blood pressure, LVEF, NYHA class III/IV, BMI, HF hospitalization within the past 6months, history of myocardial
infarction, hypertension, and atrial fibrillation, eGFR, log NT-proBNP and log diabetes duration with simple imputation of eGFR, NT-proBNP and diabetes duration.
aHRs for combined data were adjusted for within-trial clustering.
of hypoglycaemia may also be relevant. Hypoglycaemia has sev-
eral adverse CV effects such as adrenergic activation, tachycardia,
excessive compensatory vagal activation, bradycardia, myocardial
ischaemia, hypokalaemia, and QT interval prolongation, all poten-
tially leading to lethal arrhythmias.12,27,28 Insulin-treated patients
also have more adverse cardiac remodelling. Of course, these pos-
sible mechanisms are not mutually exclusive and are potentially
additive.
What are the clinical implications of our study? Patients with
insulin-treated diabetes have more congestion and physicians
should be vigilant for this and consider appropriate use of diuret-
ics to try to achieve euvolaemia. This may also help ameliorate
the substantially worse health-related quality of life in patients with
insulin-treated diabetes. More controversial is what to do about the
initiation of insulin in patients with diabetes. Insulin has the advan-
tage of being effective when combination therapy with other agents
fails to achieve the glycaemic goal and improved glycaemic control
can protect against microvascular complications that may lead to
blindness and renal failure. However, this advantage may be accom-
panied by an increase in hypoglycaemia episodes and in weight. In
addition, our findings showed insulin is associated with worse clini-
cal outcomes in HF, although this is yet to be tested in a prospective
randomized controlled trial, which is the only way of determin-
ing whether insulin is safe in HF. In the absence of such a trial, it
may be preferable to avoid insulin, if possible, especially as there is ..
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. some evidence that an alternative class of glucose-lowering agents,
the SGLT2 inhibitors, may be safe in HF.7–10 However, prospective
randomized outcome trials with these drugs in patients with estab-
lished HF are required and are now underway.29
Our study has several limitations. The most important is that
insulin treatment was not randomized and patients on insulin had
longer standing diabetes, implying a greater severity of diabetes,
and in turn, as indicated above, there were substantial differences in
baseline characteristics between patients treated with and without
insulin. While we attempted to adjust for these differences in
our multivariable analyses, unmeasured confounders could not be
accounted for.30 In one large placebo-controlled trial in patients
with pre-diabetes and established type 2 diabetes, insulin did not
increase the risk of incident or recurrent HF hospitalizations,
although patients in NYHA class III or IV were not enrolled in this
trial and the prevalence of HF at baseline was not recorded.31,32
Several other limitations should also be acknowledged. First,
our study was not prospectively planned, i.e. was retrospective.
Second, the diagnosis of diabetes was reported by investigators
without systematic documentation using standardized diagnostic
criteria. It is possible that some cases were missed. Previous
studies have identified that 8–22% of HF patients have undiag-
nosed diabetes.33–35 However, the misclassification of diabetes,
if any, would weaken rather than strengthen effect estimates.
Third, there was no differentiation between type 1 and type 2
© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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diabetes. However, the overall findings did not change in the
sensitivity analysis with the exclusion of patients having diabetes
diagnosed under 20 years of age (4.4%), who were presumably
type 1 diabetes (online supplementary Tables S1–S5 and Figure
S1). Fourth, the TOPCAT Americas data have been published
separately, although these account for only 21% of the total
patients in the present data set in which we have conducted more
comprehensive analyses.15 Finally, data on the type and dose of
insulin (and other glucose-lowering therapies), the level of gly-
caemic control (e.g. measurement of glycated haemoglobin), and
burden of microvascular complications in patients with diabetes
were not available. The trials included in this individual-patient
pooled analysis were conducted before the introduction of novel
glucose-lowering therapies including dipeptidyl peptidase-4 and
SGLT2 inhibitors and glucagon-like peptide-1 receptor agonists.
In conclusion, among patients with HFpEF, those with dia-
betes taking insulin have more evidence of congestion, worse
health-related quality of life, higher concentrations of NT-proBNP,
and worse clinical outcomes, including higher risks of HF hospital-
ization, CV death, and all-cause death, as compared to those not
treated with insulin and, particularly, individuals without diabetes.
The excess mortality in insulin-treated patients is driven by a higher
risk of sudden death. Whether the association between insulin use
and poor outcomes in HFpEF is causal should be investigated in a
prospective randomized controlled trial.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Table S1. Baseline characteristics according to baseline diabetes
mellitus status and insulin use in the combined data sets of
CHARM-Preserved (LVEF≥ 45%), I-Preserve and TOPCAT (Amer-
icas) after excluding patients with age < 20 years at diabetes onset.
Table S2. Clinical outcomes according to baseline diabetes
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patients with age < 20 years at diabetes onset.
Table S4. Clinical outcomes according to baseline diabetes
mellitus status and insulin use in the combined data sets of
CHARM-Preserved (LVEF≥ 45%), I-Preserve and TOPCAT (Amer-
icas) in patients with NT-proBNP available after excluding patients
with age < 20 years at diabetes onset.
Table S5. Clinical outcomes according to baseline insulin use in
diabetic patients in the combined data sets of CHARM-Preserved
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.. Table S7. Clinical outcomes according to baseline diabetes
mellitus status and insulin use in the combined data sets of
CHARM-Preserved (LVEF≥ 45%), I-Preserve and TOPCAT (Amer-
icas) (only patients with echocardiographic data).
Figure S1. Cumulative incidences for clinical outcomes according
to baseline diabetes mellitus status and insulin use in the combined
data sets of CHARM-Preserved (LVEF ≥ 45%), I-Preserve and
TOPCAT (Americas) after excluding patients with age < 20 years
at diabetes onset.
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